‘The new ATTR-CM treatment can improve patient survival’
By Whang, byung-woo | translator Alice Kang
24.11.27 05:19:41
가나다라
0
High prices hinder access to new treatment options introduced... stress the need for early treatment
Cited the need to diversify perspectives for their reimbursement, including considering the cost-effectiveness of treatments vs short life expectancy
Passed the Drug Reimbursement Evaluation Committee after nearly 3 years... Last barrier - drug price negotiation with the National Health Insurance Service - remains
With the possibility for reimbursement coverage for the ultra-rare disease, transthyretin amyloid cardiomyopathy (ATTR-CM) rising, excitement is also rising in the clinical site.
Due to the short life expectancy of ATTR-CM - 2-3.5 years after diagnosis – and no clear treatment option available, the benefits of a new treatment option are expected to be significant.
As an extremely rare disease with a small number of patients, challenges still remain in identifying and diagnosing patients early. Dailypharm met with Dr. Junho Hyun, Professor of Cardiology at Asan Medical Center in Seoul, to discuss Korea’s treatment environment for ATTR-CM and the changes made since the reimbursemen
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)